Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BioNTech SE - American Depositary Shares (NQ:BNTX)

96.74 -7.57 (-7.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Why BioNTech Stock Sank by More Than 7% Today
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. 
Via The Motley Fool
Topics Death Government
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths. 
Via Benzinga
Topics Government
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported. 
Via Benzinga
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside
Via Stocktwits
What Analysts Are Saying About BioNTech Stock
 
Via Benzinga
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Via Stocktwits
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
Why BioNTech Stock Crushed the Market Today
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population
Via Stocktwits
Breaking Down BioNTech: 12 Analysts Share Their Views
 
Via Benzinga
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push
Via Stocktwits
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.?
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest. 
Via Benzinga
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio?
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades. 
Via Benzinga
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing. 
Via Benzinga
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday. 
Via Investor's Business Daily
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic. 
Via Benzinga
Topics Government
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
 
Via Benzinga
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances. 
Via Chartmill
Topics Earnings
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.